SynthesisClinical rheumatology2015
Management of gout in general practice--a systematic review.
Synthesis in Clinical rheumatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 25 citations in OpenAlex.
- Association between urate-lowering therapies and cognitive decline in community-dwelling older adults.Scientific reports · 2022Trial
- Gout: a practical approach to diagnosis and management in low- and middle-income countries and resource-limited settings.Clinical rheumatology · 2026Review
- The Risk of Cardiovascular Disease among Male and Female Participants Treated for Gout in the Multi-Ethnic Study of Atherosclerosis (MESA).Gout, urate, and crystal deposition disease · 2023Article
- Beliefs of rheumatologists and general practitioners on urate lowering therapy: a cross-sectional study.Rheumatology advances in practice · 2023Article
- Gout and Hospital Admission for Ambulatory Care-Sensitive Conditions: Risks and Trajectories.The Journal of rheumatology · 2022Article
- 'It's just a great muddle when it comes to food': a qualitative exploration of patient decision-making around diet and gout.Rheumatology advances in practice · 2021Article
- Temporal trends and regional disparity in rheumatoid arthritis and gout hospitalizations in Sweden, 1998-2015.Clinical rheumatology · 2018Article
- Factors Influencing Allopurinol Initiation in Primary Care.Annals of family medicine · 2017Article
- Prevalence of comorbidities and management of gout in a tropical city in Australia.Rheumatology international · 2016Article
- Knowledge, illness perceptions and stated clinical practice behaviour in management of gout: a mixed methods study in general practice.Clinical rheumatology · 2016Article
- Improving management of gout in primary care using a customised electronic records template.BMJ quality improvement reports · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This systematic review aims to summarise published evidence that assessed the management of gout in regard to the following: prescription of urate lowering therapy (ULT), monitoring of serum urate levels (sUA) and allopurinol dosing in patients with renal impairment, lifestyle advice and acute management of gout. Studies investigating the management of gout in general practice (GP) were identified by searching PubMed and Scopus databases. To be eligible for inclusion, studies had to be focused on the GP setting alone. Studies were also excluded if they examined diagnosis without exploring management of gout. Editorials and reviews were excluded. A total of nine studies were identified. Eight studies explored the proportion of gout patients currently on ULT. Six out of the eight studies revealed that ULT was prescribed in less than 50 % of gout patients. Four studies considered the monitoring of sUA levels in gout patients. The results were generally similar throughout studies indicating sub-optimal management. Only two studies examined the monitoring of sUA levels specifically in patients who were prescribed ULT. The two studies showed 28 and 38 % of patients on ULT had their sUA levels monitored. Two studies examined the dosing of allopurinol in renally impaired patients and revealed that 74-78 % of renally impaired patients had an appropriate allopurinol dose of less than 300 mg. This systematic review suggests that gout is sub-optimally managed in general practice. However, more studies with a larger sample size focusing on active patients are required to provide more definitive evidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.